Jonathan Bernie, MD
Urology · Norwalk, CTNPI 1548352636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.5% of the total across 220 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 16.6% — the pattern of someone who eats at a lot of different presentations.
Across 220 payments — averaging $18.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sumitomo Pharma America, Inc.$682
- Astellas Pharma US Inc$496
- 180 Medical, Inc.$283
- Tolmar, Inc.$234
- Myriad Genetic Laboratories, Inc.$232
- Urovant Sciences Inc$205
- plus $2K from 31 others
What the payments were for
- Food & beverage$3,99497%
- Education$1043%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sumitomo Pharma America, Inc. | 40 | $682 |
| Astellas Pharma US Inc | 30 | $496 |
| 180 Medical, Inc. | 6 | $283 |
| Tolmar, Inc. | 11 | $234 |
| Myriad Genetic Laboratories, Inc. | 14 | $232 |
| Urovant Sciences Inc | 16 | $205 |
| Accord Healthcare, Inc. | 10 | $195 |
| Johnson & Johnson | 8 | $144 |
| AbbVie(2 entities) | 7 | $141 |
| Tolmar Pharmaceuticals, Inc. | 7 | $139 |
| Pfizer | 8 | $137 |
| Amgen | 9 | $126 |
| Urogen Pharma, Inc. | 5 | $106 |
| Ferring Pharmaceuticals Inc. | 6 | $101 |
| Coloplast | 5 | $99 |
| Neotract Inc. | 4 | $88 |
| Myovant Sciences Inc. | 5 | $83 |
| Endo Pharmaceuticals Inc. | 5 | $79 |
| Teleflex LLC | 3 | $72 |
| Olympus America Inc. | 2 | $60 |
| Bard Access Systems, Inc. | 1 | $49 |
| Merck | 2 | $47 |
| Ipsen Biopharmaceuticals, Inc | 1 | $32 |
| Verity Pharmaceuticals Inc. | 2 | $32 |
| Acerus Pharmaceuticals Corporation | 1 | $28 |
| Hollister Incorporated | 1 | $23 |
| Telix Pharmaceuticals | 1 | $23 |
| Vertex | 1 | $22 |
| Progenics Pharmaceuticals, Inc. | 1 | $22 |
| Tempus AI, Inc | 1 | $21 |
| AstraZeneca | 1 | $21 |
| Agiliti Surgical, Inc. | 1 | $19 |
| Dentsply IH Inc. | 1 | $17 |
| Antares Pharma, Inc. | 1 | $16 |
| BD | 1 | $14 |
| Metuchen Pharmaceuticals | 1 | $12 |
| Travere Therapeutics, Inc. | 1 | $2 |
How this compares
$4,099 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 87 | $88,190 |
| MyrbetriqMirabegron | 47 | $55,120 |
| Tamsulosin Hcl | 578 | $9,111 |
| Solifenacin Succinate | 34 | $4,370 |
| Finasteride | 208 | $2,947 |
| Oxybutynin Chloride ErOxybutynin Chloride | 62 | $2,709 |
| Dutasteride | 21 | $1,202 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 53 | $931 |
| Silodosin | 16 | $846 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 50 | $409 |
| Doxazosin Mesylate | 18 | $332 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $126 |
| Levofloxacin | 53 | $118 |
| Cefadroxil | 17 | $81 |
| Ciprofloxacin Hcl | 12 | $63 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $682 | $88,19087 claims |
| Astellas Pharma US IncMyrbetriq | $496 | $55,12047 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 156 urology providers in Connecticut.
Other urology in Norwalk
- Scott SerelsNorwalk$22K
- Stephen BatterNorwalk$6K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Joshua SteinNew Britain$30K
- Steven ShichmanHartford$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.